Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4

NCT05243797 is registered in ClinicalTrials.gov with European Myeloma Network B.V. as lead sponsor.

NCT NCT05243797
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05243797 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4
Lead sponsor
European Myeloma Network B.V.
Phase
Phase 3
Overall status
Recruiting
Start date
September 8, 2022
Completion date
April 30, 2032
Enrollment
1,594 (estimated)
Sites
212

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma